IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis

Background: Apremilast (Otezla®) is a phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis and psoriatic arthritis (PsA), but the reason why apremilast shows clinical effect is not fully understood. The objective of this study was to study the downstream effects of apremilast on cells of inflamed joints in immune-mediated inflammatory arthritis. Methods: Synovial fluid was obtained from patients with active rheumatoid arthritis (RA), PsA or peripheral spondyloarthritis (SpA; n = 18). The in vitro models consisted of synovial fluid mononuclear cells (SFMCs) or fibroblast-like synovial cells (FLSs) cultured for 48 h, SFMCs cultured for 21 days, an osteoclast pit formation assay, and a mineralization assay. Results: In SFMCs cultured for 48 h, apremilast decreased the production of interleukin (IL)-12/IL-23p40 (the shared subunit of IL-12 and IL-23), colony-stimulating factor 1, CD6, and CD40 and increased the production of C-X-C motif chemokine 5 dose-dependently. Apremilast had a very different response signature compared with the tumor necrosis factor alpha inhibitor adalimumab with a substantially greater inhibition of IL-12/IL-23p40. In SFMCs cultured for 21 days, apremilast increased the secretion of IL-10. In FLS cultures, apremilast decreased matrix metalloproteinase-3 production. Apremilast decreased osteoclastogenesis but did not affect mineralization by human osteoblasts. Conclusion: This study reveals the downstream effects of apremilast in ex vivo models of arthritis with a strong inhibition of IL-12/IL-23p40 by SFMCs. Our findings could explain some of the efficacy of apremilast seen in IL-12/IL-23-driven immune-mediated inflammatory diseases such as psoriasis and PsA.

[1]  T. Kragstrup,et al.  Resveratrol displays anti-inflammatory properties in an ex vivo model of immune mediated inflammatory arthritis , 2018, BMC Rheumatology.

[2]  T. Tsai,et al.  Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness , 2017, Therapeutic advances in musculoskeletal disease.

[3]  M. Boers,et al.  Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial , 2017, Annals of the Rheumatic Diseases.

[4]  G. Schett,et al.  Pathogenetic insights from the treatment of rheumatoid arthritis , 2017, The Lancet.

[5]  U. Syrbe,et al.  Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis , 2017, Journal of Molecular Medicine.

[6]  B. Schiøttz-Christensen,et al.  Increased interleukin (IL)‐20 and IL‐24 target osteoblasts and synovial monocytes in spondyloarthritis , 2017, Clinical and Experimental Immunology.

[7]  D. Crosbie,et al.  Apremilast in the treatment of psoriatic arthritis: a perspective review , 2017, Therapeutic advances in musculoskeletal disease.

[8]  J. Braun.  New targets in psoriatic arthritis. , 2016, Rheumatology.

[9]  A. Chhabra,et al.  Ankylosing Spondylitis and Axial Spondyloarthritis. , 2016, The New England journal of medicine.

[10]  W. Robinson,et al.  The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression , 2016, Arthritis Research & Therapy.

[11]  B. Cronstein,et al.  Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors , 2015, Arthritis Research & Therapy.

[12]  E. Hauge,et al.  Spontaneous generation of functional osteoclasts from synovial fluid mononuclear cells as a model of inflammatory osteoclastogenesis , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  B. Schiøttz-Christensen,et al.  Toll‐like receptor 2 and 4 induced interleukin‐19 dampens immune reactions and associates inversely with spondyloarthritis disease activity , 2015, Clinical and experimental immunology.

[14]  Peng-Yu Chen,et al.  The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1) , 2015, Journal of immunology research.

[15]  Jilly F. Evans,et al.  Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. , 2014, Cellular signalling.

[16]  W. Robinson,et al.  Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis , 2014, Arthritis Research & Therapy.

[17]  A. Gottlieb,et al.  Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. , 2013, Journal of drugs in dermatology : JDD.

[18]  A. Gottlieb,et al.  Phosphodiesterase 4-targeted treatments for autoimmune diseases , 2013, BMC Medicine.

[19]  E. Pathan,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis , 2012, Annals of the rheumatic diseases.

[20]  Ling Chen,et al.  PDE4 inhibitor suppresses PGE2-induced osteoclast formation via COX-2-mediated p27(KIP1) expression in RAW264.7 cells. , 2011, Die Pharmazie.

[21]  G. Schett,et al.  Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases , 2010, Therapeutic advances in musculoskeletal disease.

[22]  M. Feldmann,et al.  Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis , 2010, Arthritis research & therapy.

[23]  Lei Wu,et al.  Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis , 2010, British journal of pharmacology.

[24]  Soo Young Lee,et al.  PDE4 inhibitor upregulates PTH‐induced osteoclast formation via CRE‐mediated COX‐2 expression in osteoblasts , 2010, FEBS letters.

[25]  B. Strober,et al.  An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast* , 2008 .

[26]  B. Dijkmans,et al.  Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment , 2006, Annals of the rheumatic diseases.

[27]  Soo Young Lee,et al.  Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways , 2005, FEBS letters.

[28]  Changlin Li,et al.  cAMP elevators inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of p38 MAPK in Murine Peritoneal Macrophages , 2002, Cell Research.

[29]  D. Bogdanos,et al.  Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. , 2017, Autoimmunity reviews.

[30]  Julie,et al.  Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response , 2016 .

[31]  Jinsongzhang,et al.  cAMP elevators inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of p38 MAPK in Murine Peritoneal Macrophages , 2002 .

[32]  W. Eyler,et al.  PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.